Company: STAA
Filing Date: 2025-02-21
Form Type: 10-K
Source: 0000950170-25-024813
Chunk: 136

Company: STAAR SURGICAL CO
Filing Date: 2025-02-21
Form: 10-K
Item: Item 1B
Chunk 136
---
 Kong.  (2)	No other location individually exceeds 10% of the total net sales.The Company’s principal product, ICLs, are used in refractive surgery.  Historically the Company marketed and sold cataract IOLs and related injectors and injector parts.  The Company phased out sales of such products in fiscal 2023, and it did not sell any such products in fiscal 2024 and it does not expect such sales in the future. The composition of the Company’s net sales by product line was as follows (in thousands): 

        Years Ended

        2024

        2023

        2022

        ICLs
         
        $
        312,543

        $
        319,427

        $
        269,712

        Other product sales

        Cataract IOLs

        —

        1,139

        9,638

        Other surgical products(1)

        1,358

        1,849

        5,041

        Total other product sales

        1,358

        2,988

        14,679

        Total net sales
         
        $
        313,901

        $
        322,415

        $
        284,391

      	(1)	Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances. The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, U.S. and foreign export and import duties and tariffs, and political instability.

F-38

STAAR SURGICAL COMPANY AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED) 

Note 17 —Geographic AssetsThe Company’s long-lived assets are located in the following geographical locations in which the Company operates. Other than the U.S. and Switzerland, no other geographic location exceeds 10% of each category of long-lived assets. The composition of the Company’s long-lived assets was as follows (in thousands):  

        2024

        U.S.

        Switzerland

        Other(1)

        Total

        Property, plant and equipment, net
         
        $
        68,318

        $
        16,084